Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study
The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Abstract
Flumazenil (FLU), a benzodiazepine (BZD) partial agonist with a weak intrinsic activity, was previously found unable to precipitate withdrawal in tolerant subjects submitted to long‐lasting BZD treatment. The potential use of FLU to treat BZD withdrawal symptoms has also been evaluated tentatively in clinical studies. In the present experiment, FLU (treatment A) was compared with oxazepam tapering (treatment B) and placebo (treatment C) in the control of BZD withdrawal symptoms in three groups of BZD dependent patients. Group A patients (20) received FLU 1 mg twice a day for 8 days, and oxazepam 30 mg in two divided doses (15 mg + 15 mg) during the first night, oxazepam 15 mg during the second night and oxazepam 7.5 mg during the third night. FLU was injected i.v. in saline for 4 hours in the morning and 4 hours in the afternoon, in association with placebo tablets. Group B patients (20) were treated by tapering of oxazepam dosage (from 120 mg) and with saline solution (as placebo) instead of FLU for 8 days. Group C patients (10) received saline instead of FLU and placebo tablets instead of oxazepam for 8 days. FLU immediately reversed BZD effects on balance task and significantly reduced withdrawal symptoms in comparison with oxazepam and placebo on both self‐reported and observer‐rated withdrawal scales. The partial agonist also reduced craving scores during the detoxification procedure. In addition, during oxazepam tapering, group B patients experienced paradoxical symptoms that were not apparent in FLU patients. Patients treated with FLU showed a significantly lower relapse rates on days 15, 23 and 30 after the detoxification week. Our data provide further evidence of FLUs ability to counteract BZD effects, control BZD withdrawal and normalize BZD receptor function. The effectiveness of FLU may reflect its capacity to upregulate BZD receptors and to reverse the uncoupling between the recognition sites of BZD and GABA, on the GABA A macromolecular complex, that has been reported in tolerant subjects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While limited evidence was found comparing tapering strategies, the systematic review identified two RCTs with 70 participants that compared a BZD taper to abrupt cessation.60,61”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [60]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 2×
“The partial-agonist promptly reversed BZD effects, as demonstrated by the significant increase in balance task time, without precipitating severe withdrawal symptoms, in agreement with previous findings.(8,10,19,26) Our data also showed FLU’s capability to reduce craving during the detoxification period, in comparison…”
MethodResultThe assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation
Reitan, R. M., & Wolfson, D. E. (1993) · Medical Entomology and Zoology · Cited by 3,854
Selective antagonists of benzodiazepines
Hunkeler, W., Möhler, H., Pieri, L., Polc, P., Bonetti, E. P., Cumin, R., Schaffner, R., & Haefely, W. (1981) · Nature · doi:10.1038/290514a0 · Cited by 1,232
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
Benzodiazepine withdrawal: an unfinished story.
Ashton, H. (1984) · BMJ · doi:10.1136/bmj.288.6424.1135 · Cited by 291
Nutt, D. J. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220033004 · Cited by 272 · cited 1×
“A possible explanation for FLU effects, including tolerance reversal and withdrawal symptom attenuation might be found in FLU’s capacity to normalize and upregulate BZD receptors.(16,22) The specific mechanism of action of partial BZD agonists in the receptor normalization process seems to be FLU’s ability to restore…”
BackgroundGradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271
WHITWAM, J. G., & AMREIN, R. (1995) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1995.tb04374.x · Cited by 257
Research works printed but not linked: 8
- Vescovi PP, 1987, Nicotinic acid effectiveness in the treatment of benzodiazepine withdrawal, CurrTherRes, 41, 429
- 10.1097/00004850-199611020-00002 · doi:10.1097/00004850-199611020-00002
- Spitzer RL, 1990, Structured Clinical Interview according to DSM‐III‐R
- Pfohl B, 1989, Structured Interview for Personality Disorders, revised version
- Hathaway SR, 1989, Minnesota Multifasic Personality Inventory‐2. Manual
- Wechsler CD., 1985, WAIS‐R manual
- Peturrson H, 1984, Dependence on tranquilizers
- 10.1111/j.1572-0241.2000.01866.x · doi:10.1111/j.1572-0241.2000.01866.x · Paper page
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Loss of GABAergic Signaling by AgRP Neurons to the Parabrachial Nucleus Leads to Starvation
Wu, Q., Boyle, M. P., & Palmiter, R. D. (2009) · Cell · doi:10.1016/j.cell.2009.04.022 · Cited by 465
“In parallel with a clinical study showing that flumazenil treatment alleviated the withdrawal syndrome (Gerra et al., 2002), our results demonstrate that bretazenil-mediated restoration of food intake was completely abolished by the fourth ventricle administration of flumazenil.”
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“Flumazenil-treated patients also had greater abstinence rates post detoxification (Gerra et al., 2002) (Ib).”
BackgroundWithdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
“[81]).”
Metadata
- Authors
- Gerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C.
- Corresponding author
- Gerra, G.
- ORCID
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2002-10
- Volume
- 7
- Issue
- 4
- Pages
- 385-395
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W2091589270
- Cited by
- 82
- References
- 42
- Citations by year
- 2025: 4 · 2024: 1 · 2022: 8 · 2021: 5 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 5 · 2012: 10
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Addiction Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- flumazenil, benzodiazepine withdrawal, benzodiazepine dependence, benzodiazepine tolerance, withdrawal symptoms, craving, detoxification, relapse, paradoxical effects, GABAA receptor
- MeSH terms
- Adult, Antidotes, Benzodiazepines, Blood Pressure, Cognition Disorders, Drug Administration Schedule, Female, Flumazenil, Heart Rate, Humans, Injections, Intravenous, Male, MMPI, Oxazepam, Personality Disorders, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Wechsler Scales, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. https://app.cochat.ai/papers/10.1080/1355621021000005973
- The paper
- Gerra, G., Zaimovic, A., Giusti, F., Moi, G., & Brewer, C. (2002). Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo‐controlled study. Addiction Biology. https://doi.org/10.1080/1355621021000005973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.